IMMX has 36-month beta value of 0.18. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMMX is 13.85M, and currently, short sellers hold a 2.81% ratio of that float. The average trading volume of IMMX on April 19, 2024 was 283.38K shares.
IMMX) stock’s latest price update
The stock of Immix Biopharma Inc (NASDAQ: IMMX) has decreased by -11.60 when compared to last closing price of 2.50.Despite this, the company has seen a loss of -23.53% in its stock price over the last five trading days. Seeking Alpha reported 2023-12-03 that Immix Biopharma is a biotech company focused on developing CAR-T and other cell-based therapies for cancers and heme disorders. Their most advanced project is NXC-201, a BCMA-targeted CAR-T natural killer cell therapy, which has shown a 95% overall response rate in patients with multiple myeloma. They also have a tissue-specific platform called iMX-110, which is being assessed in early-stage studies for sarcoma and colorectal cancer.
IMMX’s Market Performance
Immix Biopharma Inc (IMMX) has experienced a -23.53% fall in stock performance for the past week, with a -19.93% drop in the past month, and a -58.69% drop in the past quarter. The volatility ratio for the week is 14.55%, and the volatility levels for the past 30 days are at 11.03% for IMMX. The simple moving average for the past 20 days is -23.66% for IMMX’s stock, with a -37.38% simple moving average for the past 200 days.
IMMX Trading at -26.81% from the 50-Day Moving Average
After a stumble in the market that brought IMMX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.48% of loss for the given period.
Volatility was left at 11.03%, however, over the last 30 days, the volatility rate increased by 14.55%, as shares sank -19.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.91% lower at present.
During the last 5 trading sessions, IMMX fell by -23.53%, which changed the moving average for the period of 200-days by -25.84% in comparison to the 20-day moving average, which settled at $2.87. In addition, Immix Biopharma Inc saw -68.06% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMMX starting from Hsu Jason, who purchase 31,000 shares at the price of $4.67 back on Dec 11 ’23. After this action, Hsu Jason now owns 813,000 shares of Immix Biopharma Inc, valued at $144,894 using the latest closing price.
Hsu Jason, the Director of Immix Biopharma Inc, purchase 25,000 shares at $4.88 during a trade that took place back on Dec 08 ’23, which means that Hsu Jason is holding 782,000 shares at $122,025 based on the most recent closing price.
Stock Fundamentals for IMMX
The total capital return value is set at -1.0. Equity return is now at value -104.35, with -88.57 for asset returns.
Currently, EBITDA for the company is -16.13 million with net debt to EBITDA at 1.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.32.
Conclusion
To put it simply, Immix Biopharma Inc (IMMX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
